Right Ventricular Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis.
Right Ventricular Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis.
复制标题
DOI:
10.1053/j.jvca.2021.04.008
复制
发表时间:
2021-11
影响因子:
2.8
通讯作者:
Guarracino F
中科院分区:
文献类型:
--
作者:
Paternoster G;Bertini P;Innelli P;Trambaiolo P;Landoni G;Franchi F;Scolletta S;Guarracino F
This systematic review and meta-analysis aimed to describe the features of right ventricular impairment and pulmonary hypertension in coronavirus disease (COVID-19) and assess their effect on mortality. The authors carried out a systematic review and meta-analysis of observational studies. The authors performed a search through PubMed, the International Clinical Trials Registry Platform, and the Cochrane Library for studies reporting right ventricular dysfunction in patients with COVID-19 and outcomes. The search yielded nine studies in which the appropriate data were available. Interventions: Pooled odds ratios were calculated according to the random-effects model. Overall, 1,450 patients were analyzed, and half of them were invasively ventilated. Primary outcome was mortality at the longest follow-up available. Mortality was 48.5% versus 24.7% in patients with or without right ventricular impairment (n = 7; OR = 3.10; 95% confidence interval [CI] 1.72-5.58; p = 0.0002), 56.3% versus 30.6% in patients with or without right ventricular dilatation (n = 6; OR = 2.43; 95% CI 1.41-4.18; p = 0.001), and 52.9% versus 14.8% in patients with or without pulmonary hypertension (n = 3; OR = 5.75; 95% CI 2.67-12.38; p < 0.001). Mortality in patients with COVID-19 requiring respiratory support and with a diagnosis of right ventricular dysfunction, dilatation, or pulmonary hypertension is high. Future studies should highlight the mechanisms of right ventricular derangement in COVID-19, and early detection of right ventricular impairment using ultrasound might be important to individualize therapies and improve outcomes.
登录
查看更多内容
DOI:
10.1186/s13054-020-03385-5
发表时间:
2020-11-30
期刊:
Critical care (London, England)
影响因子:
--
作者:
D'Alto M;Marra AM;Severino S;Salzano A;Romeo E;De Rosa R;Stagnaro FM;Pagnano G;Verde R;Murino P;Farro A;Ciccarelli G;Vargas M;Fiorentino G;Servillo G;Gentile I;Corcione A;Cittadini A;Naeije R;Golino P
通讯作者:
Golino P
影响因子:
2.8
作者:
De Cobelli F;Palumbo D;Ciceri F;Landoni G;Ruggeri A;Rovere-Querini P;D'Angelo A;Steidler S;Galli L;Poli A;Fominskiy E;Calabrò MG;Colombo S;Monti G;Nicoletti R;Esposito A;Conte C;Dagna L;Ambrosio A;Scarpellini P;Ripa M;Spessot M;Carlucci M;Montorfano M;Agricola E;Baccellieri D;Bosi E;Tresoldi M;Castagna A;Martino G;Zangrillo A
通讯作者:
Zangrillo A
DOI:
10.1016/s2213-2600(20)30370-2
发表时间:
2020-12
期刊:
The Lancet. Respiratory medicine
影响因子:
--
作者:
Grasselli G;Tonetti T;Protti A;Langer T;Girardis M;Bellani G;Laffey J;Carrafiello G;Carsana L;Rizzuto C;Zanella A;Scaravilli V;Pizzilli G;Grieco DL;Di Meglio L;de Pascale G;Lanza E;Monteduro F;Zompatori M;Filippini C;Locatelli F;Cecconi M;Fumagalli R;Nava S;Vincent JL;Antonelli M;Slutsky AS;Pesenti A;Ranieri VM;collaborators
通讯作者:
collaborators
DOI:
10.1111/echo.14837
发表时间:
2020-08-29
影响因子:
1.5
作者:
Garcia-Cruz, Edgar;Manzur-Sandoval, Daniel;Baranda-Tovar, Francisco
通讯作者:
Baranda-Tovar, Francisco
DOI:
10.1016/s0140-6736(20)32008-0
发表时间:
2020-10-10
期刊:
Lancet (London, England)
影响因子:
--
作者:
Barbaro RP;MacLaren G;Boonstra PS;Iwashyna TJ;Slutsky AS;Fan E;Bartlett RH;Tonna JE;Hyslop R;Fanning JJ;Rycus PT;Hyer SJ;Anders MM;Agerstrand CL;Hryniewicz K;Diaz R;Lorusso R;Combes A;Brodie D;Extracorporeal Life Support Organization
通讯作者:
Extracorporeal Life Support Organization